With the tumultuous rollout of Aduhelm behind them, partners Biogen and Eisai have the rare opportunity for a do-over, with all-important data on their next Alzheimer’s disease therapy expected next month.
This week on “The Readout LOUD” podcast: How does a startup compete in the rapidly evolving field of weight loss drugs? And how did a…
A WHO advisory committee outlined a new set of definitions that more accurately reflect the science of airborne disease transmission.
For some, Microsoft’s deep involvement in setting standards for the use of AI in health care raises questions about “regulatory capture.”
Health insurer Elevance’s private equity deal will form a $4 billion primary care company.
A new analysis of health inequities shows that every state has deep racial and ethnic disparities in the performance of their health care systems.
For more than two years, Sen. Chuck Schumer has been promising to hold a vote to make insulin affordable for people with all types of…
“It is good to see this institution taking a harder stance against sloppy science and intentional data falsification that many institutes have done in the…
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess…
As lawmakers take aim at WuXi Apptec, the issue is testing the ability of BIO’s CEO to navigate a domestic policy issue that is tangled…
Our latest edition of D.C. Diagnosis includes the backstory of BIO’s relationship with WuXi, a major endorsement of site-neutral payments, and the financial fallout of…
